Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 May;42(4):742-745.
doi: 10.1007/s10875-022-01235-3. Epub 2022 Mar 17.

Transient Increase of Pre-existing Anti-IFN-α2 Antibodies Induced by SARS-CoV-2 Infection

Sophie Steels #  1 , Jan Van Elslande #  1 ; Leuven COVID-Study Group; Paul De Munter  2   3 , Xavier Bossuyt  4   5
Collaborators, Affiliations
Comment

Transient Increase of Pre-existing Anti-IFN-α2 Antibodies Induced by SARS-CoV-2 Infection

Sophie Steels et al. J Clin Immunol. 2022 May.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Antibodies to IFN-α2 in controls and in COVID-19 patients. Panel A. Antibodies to IFN-α2 were measured in 15 healthy controls, in 6 patients with pre-COVID-19 antibody levels that were comparable to the antibody levels in the 15 controls (cases 1–6), in 2 patients with pre-COVID anti-IFN-α2 antibodies (cases 7–8) and in 2 patients with anti-IFN-α2 antibodies but for whom with no pre-COVID samples were available (cases 9–10). In COVID-19 patients, antibody levels were measured in pre-COVID-19 samples, during and post-COVID-19. The results are from a representative experiment out of 2 experiments. Controls are represented by open symbols, cases by filled symbols. In the X-axis, the number of days before infection or the number of days post-infection are indicated (first positive PCR for SARS-CoV-2 is day 0). Panel B. STAT-1 phosphorylation in the presence of 10% serum in unstimulated (red line) or stimulated (10 ng/mL IFN-α2) cells (blue line). The distribution of the fluorescence intensities is shown. The results for patient case 7 are shown with serum obtained before (day − 1264), during (day 2) and after (day 345) SARS-CoV-2 infection. Panel C. Neutralizing capacity of 10% serum on whole blood STAT-1 phosphorylation. STAT-1 phosphorylation was evaluated in 6 controls and three patients (cases 6, 7, and 8). For each patient, three serum samples (pre-infection, during infection, and post-infection) were evaluated. The ratio of the median fluorescence intensity in IFN-α2-stimulated to unstimulated cells was calculated. A ratio of 1 indicates that IFN-α2-induced STAT1 phosphorylation was abolished, suggesting the presence of neutralizing antibodies. The days before or after the first positive PCR for SARS-CoV-2 are indicated (first positive PCR is day 0)
See this image and copyright information in PMC

Comment on

  • Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths.
    Bastard P, Gervais A, Le Voyer T, Rosain J, Philippot Q, Manry J, Michailidis E, Hoffmann HH, Eto S, Garcia-Prat M, Bizien L, Parra-Martínez A, Yang R, Haljasmägi L, Migaud M, Särekannu K, Maslovskaja J, de Prost N, Tandjaoui-Lambiotte Y, Luyt CE, Amador-Borrero B, Gaudet A, Poissy J, Morel P, Richard P, Cognasse F, Troya J, Trouillet-Assant S, Belot A, Saker K, Garçon P, Rivière JG, Lagier JC, Gentile S, Rosen LB, Shaw E, Morio T, Tanaka J, Dalmau D, Tharaux PL, Sene D, Stepanian A, Megarbane B, Triantafyllia V, Fekkar A, Heath JR, Franco JL, Anaya JM, Solé-Violán J, Imberti L, Biondi A, Bonfanti P, Castagnoli R, Delmonte OM, Zhang Y, Snow AL, Holland SM, Biggs C, Moncada-Vélez M, Arias AA, Lorenzo L, Boucherit S, Coulibaly B, Anglicheau D, Planas AM, Haerynck F, Duvlis S, Nussbaum RL, Ozcelik T, Keles S, Bousfiha AA, El Bakkouri J, Ramirez-Santana C, Paul S, Pan-Hammarström Q, Hammarström L, Dupont A, Kurolap A, Metz CN, Aiuti A, Casari G, Lampasona V, Ciceri F, Barreiros LA, Dominguez-Garrido E, Vidigal M, Zatz M, van de Beek D, Sahanic S, Tancevski I, Stepanovskyy Y, Boyarchuk O, Nukui Y, Tsumura M, Vidaur L, Tangye SG, Burrel S, Duffy D, Quintana-Murci L, Klocperk A, Kann NY,… See abstract for full author list ➔ Bastard P, et al. Sci Immunol. 2021 Aug 19;6(62):eabl4340. doi: 10.1126/sciimmunol.abl4340. Sci Immunol. 2021. PMID: 34413139 Free PMC article.

References

    1. Bastard P, Gervais A, Le Voyer T, Rosain J, Philippot Q, Manry J, et al. Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. Sci Immunol. 2021;6(62):eabl4340. - PMC - PubMed
    1. Bastard P, Rosen LB, Zhang Q, Michailidis E, Hoffmann HH, Zhang Y, et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science 2020 23;370(6515):eabd4585. - PMC - PubMed
    1. Qu J, Wu C, Li X, Zhang G, Jiang Z, Li X, et al. Profile of IgG and IgM antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Clin Infect Dis. 2020;71:2255–2258. doi: 10.1093/cid/ciaa489. - DOI - PMC - PubMed
    1. Guldager DKR, von Stemann JH, Larsen R, Bay JT, Galle PS, Svenson M, et al. A rapid, accurate and robust particle-based assay for the simultaneous screening of plasma samples for the presence of five different anti-cytokine autoantibodies. J Immunol Methods. 2015;425:62–68. doi: 10.1016/j.jim.2015.06.010. - DOI - PubMed
    1. Bello-Rivero I, Cervantes M, Torres Y, Ferrero J, Rodríguez E, Pérez J, García I, Díaz G, López-Saura P. Characterization of the immunoreactivity of anti-interferon alpha antibodies in myasthenia gravis patients. Epitope mapping J Autoimmun. 2004;23(1):63–73. doi: 10.1016/j.jaut.2004.03.013. - DOI - PubMed

Substances